查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598384

地中海型貧血治療市場：按類型、適應症、最終用戶分類 - 2025-2030 年全球預測

Thalassemia Treatment Market by Type (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation), Indication Type (Alpha Thalassemia, Beta Thalassemia), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

地中海貧血治療市場2023年估值為63.8億美元，預計2024年將達到70.6億美元，複合年成長率為12.31%，到2030年將達到143.8億美元。

地中海貧血治療包括旨在控制這種遺傳性血液疾病的醫療策略，該疾病的特徵是血紅蛋白生成受損並導致貧血和其他併發症。改善患者生活品質、減少對定期輸血的依賴以及預防鐵超載等併發症的需求推動了對地中海貧血有效治療的需求。治療應用包括常規輸血、鐵螯合療法和新興基因療法，最終用途主要用於醫院、專科診所和居家醫療環境。根據市場洞察，基因治療的進步和亞太地區及其他地區地中海貧血盛行率的增加是主要的成長要素。此外，制定個人化治療計劃和整合數位健康技術來管理患者資料和治療方法依從性也具有巨大潛力。然而，治療成本上升、低收入國家認知度低以及新療法需要嚴格監管核准等因素對市場成長構成了挑戰。創新的關鍵領域包括開發具有成本效益的基因編輯技術、針對更廣泛的地中海貧血突變的治療方法設計以及在治療結果評估中使用人工智慧進行預測分析。企業應專注於建立策略夥伴關係，加強研發力度，並加速臨床試驗。隨時了解最新的技術進步和監管變化以抓住新機會非常重要。另一方面，促進教育計劃和提高公眾意識有助於緩解市場限制。市場動態的動態性和簡化護理的持續努力為旨在改變患者照護的創新提供了肥沃的土壤。

主要市場統計
基準年[2023] 63.8億美元
預測年份 [2024] 70.6億美元
預測年份 [2030] 143.8億美元
複合年成長率（%） 12.31%

市場動態：揭示快速發展的地中海貧血治療市場的關鍵市場洞察

供需的動態交互作用正在改變地中海貧血治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 地中海型貧血人口增加
    • 對地中海貧血早期診斷與治療的認知
    • 基因組研究日益受到重視
  • 市場限制因素
    • 地中海貧血治療相關的高成本
  • 市場機會
    • 地中海貧血新療法的核准數量增加
    • 各國醫療基礎建設支出增加
  • 市場挑戰
    • 與地中海貧血治療相關的可能併發症

波特五力：駕馭地中海型貧血治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解地中海貧血治療市場的外部影響

外部宏觀環境因素在塑造地中海貧血治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解地中海貧血治療市場的競爭狀況

對地中海貧血治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣地中海貧血治療市場供應商的績效評估

FPNV 定位矩陣是評估地中海貧血治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製地中海貧血治療市場的成功之路

地中海貧血治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中地中海貧血的發生率不斷增加
      • 對地中海貧血早期診斷與治療的認知
      • 基因組研究的重要性日益增加
    • 抑制因素
      • 地中海貧血治療相關的高費用
    • 機會
      • 核准的地中海貧血新藥數量增加
      • 各國醫療基礎建設支出增加
    • 任務
      • 與地中海貧血治療相關的可能併發症
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章地中海貧血治療市場：依類型

  • 輸血
  • 骨髓和幹細胞移植
  • 鐵螯合
  • 魯斯帕特西普

第7章地中海型貧血治療市場（依適應症類型）

  • α地中海貧血
  • BETA地中海型貧血

第8章地中海貧血治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第9章美洲地中海貧血治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區地中海貧血治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲地中海貧血治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ApoPharma Inc.
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine Inc.
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd.
  • GL Pharma
  • Grifols International SA
  • Ionis Pharmaceuticals, Inc.
  • La Jolla Pharmaceutical Company
  • Lonza Group AG
  • Macsen Laboratories
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Pharmascience Inc.
  • Rajasthan Antibiotics Ltd
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-C002B1C996FB

The Thalassemia Treatment Market was valued at USD 6.38 billion in 2023, expected to reach USD 7.06 billion in 2024, and is projected to grow at a CAGR of 12.31%, to USD 14.38 billion by 2030.

Thalassemia treatment encompasses medical strategies aimed at managing this inherited blood disorder characterized by faulty hemoglobin production, leading to anemia and other complications. The necessity of effective thalassemia treatments is driven by the need to improve patients' quality of life, reduce dependence on regular blood transfusions, and prevent complications like iron overload. Treatment applications include regular blood transfusions, iron chelation therapy, and emerging gene therapies, with end-use primarily among hospitals, specialty clinics, and homecare settings. Market insights reveal that advances in gene therapy and the increasing prevalence of thalassemia in regions such as Asia-Pacific are major growth factors. Furthermore, there is considerable potential in developing personalized treatment plans and integrating digital health technologies to manage patient data and adherence to treatment regimens. However, market growth is challenged by factors like the high cost of treatments, a lack of awareness in low-income countries, and the need for stringent regulatory approvals for new therapies. Key areas for innovation include developing cost-effective gene-editing technologies, crafting therapies that target a broader spectrum of thalassemia mutations, and leveraging AI for predictive analytics in treatment outcome assessments. Companies should focus on building strategic collaborations to enhance R&D efforts and accelerate clinical trials. Staying updated with the latest technological advancements and regulatory changes is crucial to capture emerging opportunities. Meanwhile, promoting educational programs and raising public awareness can aid in mitigating market limitations. The nature of the thalassemia treatment market is dynamic, with ongoing efforts to streamline therapies making it a fertile ground for innovations aimed at transformative patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 6.38 billion
Estimated Year [2024] USD 7.06 billion
Forecast Year [2030] USD 14.38 billion
CAGR (%) 12.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thalassemia Treatment Market

The Thalassemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of thalassemia disorders among population
    • Awareness related to early diagnosis and treating thalassemia
    • Growing emphasis on genomic research
  • Market Restraints
    • High cost associated with thalassemia treatments
  • Market Opportunities
    • Rising number of approvals for novel thalassemia treatments
    • Increasing healthcare infrastructure spendings across economies
  • Market Challenges
    • Possible complications associated with thalassemia therapies

Porter's Five Forces: A Strategic Tool for Navigating the Thalassemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thalassemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thalassemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thalassemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thalassemia Treatment Market

A detailed market share analysis in the Thalassemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thalassemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thalassemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thalassemia Treatment Market

A strategic analysis of the Thalassemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thalassemia Treatment Market, highlighting leading vendors and their innovative profiles. These include ApoPharma Inc., Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics AG, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd., GL Pharma, Grifols International SA, Ionis Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Lonza Group AG, Macsen Laboratories, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Pharmascience Inc., Rajasthan Antibiotics Ltd, Sangamo Therapeutics, Inc., Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Thalassemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation, and Luspatercept.
  • Based on Indication Type, market is studied across Alpha Thalassemia and Beta Thalassemia.
  • Based on End-Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of thalassemia disorders among population
      • 5.1.1.2. Awareness related to early diagnosis and treating thalassemia
      • 5.1.1.3. Growing emphasis on genomic research
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with thalassemia treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising number of approvals for novel thalassemia treatments
      • 5.1.3.2. Increasing healthcare infrastructure spendings across economies
    • 5.1.4. Challenges
      • 5.1.4.1. Possible complications associated with thalassemia therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thalassemia Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Blood Transfusion
  • 6.3. Bone Marrow & Stem Cell Transplant
  • 6.4. Iron Chelation
  • 6.5. Luspatercept

7. Thalassemia Treatment Market, by Indication Type

  • 7.1. Introduction
  • 7.2. Alpha Thalassemia
  • 7.3. Beta Thalassemia

8. Thalassemia Treatment Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Thalassemia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thalassemia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thalassemia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ApoPharma Inc.
  • 2. Bellicum Pharmaceuticals, Inc.
  • 3. bluebird bio, Inc.
  • 4. Bristol-Myers Squibb Company
  • 5. CRISPR Therapeutics AG
  • 6. Editas Medicine Inc.
  • 7. Errant Gene Therapeutics LLC
  • 8. Gamida Cell Ltd.
  • 9. GL Pharma
  • 10. Grifols International SA
  • 11. Ionis Pharmaceuticals, Inc.
  • 12. La Jolla Pharmaceutical Company
  • 13. Lonza Group AG
  • 14. Macsen Laboratories
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Pfizer, Inc.
  • 19. Pharmascience Inc.
  • 20. Rajasthan Antibiotics Ltd
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sanofi S.A.
  • 23. Taj Pharmaceuticals Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. THALASSEMIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. THALASSEMIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THALASSEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THALASSEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THALASSEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THALASSEMIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY IRON CHELATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. THALASSEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. THALASSEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023